<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35388183</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki.</ArticleTitle><Pagination><StartPage>3563</StartPage><EndPage>3564</EndPage><MedlinePgn>3563-3564</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-022-01546-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Yaeko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respirology, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Takuji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respirology, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8892-0439</Identifier><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan. hashimoto@faculty.chiba-u.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Mol Psychiatry. 2022 Apr;27(4):1898-1907. doi: 10.1038/s41380-021-01432-3</RefSource><PMID Version="1">34997196</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Mol Psychiatry. 2022 Sep;27(9):3562. doi: 10.1038/s41380-022-01545-3</RefSource><PMID Version="1">35388182</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="N">Fluvoxamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="Y">Receptors, sigma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097605" MajorTopicYN="N">Sigma-1 Receptor</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>YH and TS have no conflict of interest. KH is the inventor of filed patent applications on &#x201c;The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases&#x201d;, &#x201c;(<i>S</i>)-norketamine and salt thereof as pharmaceutical&#x201d;, &#x201c;<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder&#x201d;, &#x201c;Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases&#x201d;, and &#x201c;<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder&#x201d; by the Chiba University. KH has also received speakers&#x2019; honoraria, consultant fee, or research support from Abbott, Meiji Seika Pharma, Daiichi-Sankyo, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35388183</ArticleId><ArticleId IdType="pmc">PMC8985059</ArticleId><ArticleId IdType="doi">10.1038/s41380-022-01546-2</ArticleId><ArticleId IdType="pii">10.1038/s41380-022-01546-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiatry. 2021;78:682&#x2013;3. doi: 10.1001/jamapsychiatry.2021.0500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.0500</ArticleId><ArticleId IdType="pmc">PMC9894299</ArticleId><ArticleId IdType="pubmed">33769431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021;11:10902. doi: 10.1038/s41598-021-90351-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90351-y</ArticleId><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Khani E, Entezari-Maleki T. Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists. Mol Psychiatry. 2022; 10.1038/s41380-022-01545-3. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8985056</ArticleId><ArticleId IdType="pubmed">35388182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci. 2022;272:161&#x2013;3. doi: 10.1007/s00406-021-01326-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-021-01326-z</ArticleId><ArticleId IdType="pmc">PMC8412866</ArticleId><ArticleId IdType="pubmed">34476589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021;271:249&#x2013;58. doi: 10.1007/s00406-020-01231-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-020-01231-x</ArticleId><ArticleId IdType="pmc">PMC7785036</ArticleId><ArticleId IdType="pubmed">33403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry. 2022. 1&#x2013;10. 10.1038/s41380-021-01432-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8739627</ArticleId><ArticleId IdType="pubmed">34997196</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DA, Seki SM, Fern&#xe1;ndez-Casta&#xf1;eda A, Beiter RM, Eccles JD, Woodfolk JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11:eaau5266. doi: 10.1126/scitranslmed.aau5266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau5266</ArticleId><ArticleId IdType="pmc">PMC6936250</ArticleId><ArticleId IdType="pubmed">30728287</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Farre B, Rovira J, Martinez D, Valera A, Garcia-Herrera A, Marcos MA, et al. In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. Mod Pathol. 2014;27:1599&#x2013;611. doi: 10.1038/modpathol.2014.68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2014.68</ArticleId><ArticleId IdType="pubmed">24762547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>